RIGEL PHARMACEUTICALS INC (RIGL) presents a materially improved balance sheet as of March 31, 2026 relative to its historical posture, though the liquidation lens still produces a meaningfully negative equity recovery given the standard haircut framework applied to MFFAIS-reported values. Total assets of $504.6M are dominated by three categories: (1) cash and short-term investments of $146.7M (100% recoverable), (2) a deferred income tax asset of $243.3M (0% recoverable under liquidation—no acquirer pays face value for a target's NOL/DTA stack), and (3) finite-lived intangibles of $24.2M net (0% under the intangibles haircut). Stripping out the DTA and intangibles, liquid and tangible asset recovery narrows to roughly $185-190M. Against total liabilities of $104.7M at face value—including $45.0M in term loan principal outstanding (all due within 12 months based on maturity schedule disclosed), $28.1M in gross-to-net sales reserves (ContractWithCustomerRefundLiabilityCurrent), and a $5.0M contingent consideration liability from the Blueprint GAVRETO acquisition—the nominal equity cushion evaporates when the DTA is zeroed. The MFFAIS-reported cash liquidation value of -$110.3M and liquid liquidation value of -$60.4M are consistent with this read. The DTA of $243.3M, recognized in Q4 2025 following a full valuation allowance release ($245.9M benefit booked in FY2025), represents the single largest balance sheet item and is entirely non-recoverable in liquidation. Its presence inflates book equity ($399.9M) and GAAP total assets but contributes zero to orderly wind-down proceeds. AR of $49.9M at 90-95% recovery and inventory of $11.7M at 60% add approximately $52M combined. The $122.3M in short-term investments (available-for-sale debt securities, amortized cost $123.5M, fair value $123.4M) is near-100% liquid. A material post-period structural change is the May 5, 2026 termination of the $45M MidCap term loan and replacement with a new $40M revolving credit facility; at filing date only $8.0M was drawn. The prior period comparison (FY2025 10-K, period end December 31, 2025) shows the DTA was newly recognized in Q4 2025, marking the principal balance-sheet change QoQ. The Lilly collaboration termination (effective June 15, 2026) eliminates a future milestone/royalty revenue stream but does not directly affect balance-sheet recovery. GAVRETO's December 2025 boxed warning and the associated commercial uncertainty are relevant to ongoing cash generation but do not independently move the liquidation calculus. The accumulated deficit stands at -$1.014B.
▼ Community Notes